Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bešević Jelena, Gunter Marc J, Fortner Renée T, Tsilidis Konstantinos K, Weiderpass Elisabete, Onland-Moret N Charlotte, Dossus Laure, Tjønneland Anne, Hansen Louise, Overvad Kim, Mesrine Sylvie, Baglietto Laura, Clavel-Chapelon Françoise, Kaaks Rudolf, Aleksandrova Krasimira, Boeing Heiner, Trichopoulou Antonia, Lagiou Pagona, Bamia Christina, Masala Giovanna, Agnoli Claudia, Tumino Rosario, Ricceri Fulvio, Panico Salvatore, Bueno-de-Mesquita H Bas, Peeters Petra H, Jareid Mie, Quirós J Ramón, Duell Eric J, Sánchez María-José, Larrañaga Nerea, Chirlaque María-Dolores, Barricarte Aurelio, Dias Joana A, Sonestedt Emily, Idahl Annika, Lundin Eva, Wareham Nicholas J, Khaw Kay-Tee, Travis Ruth C, Rinaldi Sabina, Romieu Isabelle, Riboli Elio, Merritt Melissa A
Аннотация
METHODS: Information on reproductive characteristics was collected at recruitment. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), and multivariable models were adjusted for age and year of diagnosis, body mass index, tumour stage, smoking status and stratified by study centre.
RESULTS: After a mean follow-up of 3.6 years (±3.2 s.d.) following EOC diagnosis, 511 (49.9%) of the 1025 women died from EOC. We observed a suggestive survival advantage in menopausal hormone therapy (MHT) users (ever vs never use, HR=0.80, 95% CI=0.62-1.03) and a significant survival benefit in long-term MHT users (⩾5 years use vs never use, HR=0.70, 95% CI=0.50-0.99, P(trend)=0.04). We observed similar results for MHT use when restricting to serous cases. Other reproductive factors, including parity, breastfeeding, oral contraceptive use and age at menarche or menopause, were not associated with EOC-specific mortality risk.
CONCLUSIONS: Further studies are warranted to investigate the possible improvement in EOC survival in MHT users.